Search results

With funds equivalent to just 2.9 percent ($35.7 billion) of their combined annual military spending, Group of Seven (G7) countries could help end world hunger and solve the debt crisis in the Global South, reveals new Oxfam analysis ahead of the G7 Summit in Borgo Egnazia, Italy.

The leaders of over 20 major aid agencies working in Gaza are calling on world leaders to urgently intervene after a UN commission concluded, for the first time, that genocide is being committed.  

Poor countries are cutting back investment in farming, health service and services to help women because of fears about rising debts and the impact of the economic crisis, according to a new database launched today. 

Agencies fear recent improvements will be wiped out as the number of severely hungry people will rise by one million in first three months of 2015.

Agriculture is highly sensitive to climate variability and weather extremes.

More than two years on from the escalation of the war in Ukraine, women and girls’ humanitarian needs remain unmet. The gendered impacts of the war are being overlooked, pre-existing gender-based inequalities are being exacerbated and Women’s Rights and Women-Led Organizations (WROs/WLOs) are being largely excluded from the humanitarian coordination, decision making and funding systems in Ukraine. 

Oxfam’s humanitarian work in Iraq is restricted due to heightened security concerns, road checkpoints and travel difficulties, following Iranian missile attacks on US military bases in Iraq overnight in retaliation for the US killing of the Iranian General Suleimani.

Tens of thousands of people have seen their homes flattened or damaged to such an extent that it is not safe for them to return.

Violence against women and girls is a global crisis, already affecting one in three women in their lifetime, devastating their lives and fracturing communities. It is time to say 'Enough'.

Pharmaceutical giant Novartis is back in court this week, in a renewed attempt to block India’s right to produce affordable ‘generic’ versions of the company’s branded medicines.